NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 207 filers reported holding NEKTAR THERAPEUTICS in Q1 2017. The put-call ratio across all filers is 0.37 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2022 | $32,393 | -36.5% | 14,333 | -10.0% | 0.00% | – |
Q3 2022 | $51,000 | -15.0% | 15,921 | 0.0% | 0.00% | – |
Q2 2022 | $60,000 | -32.6% | 15,921 | -3.4% | 0.00% | – |
Q1 2022 | $89,000 | -60.1% | 16,488 | 0.0% | 0.00% | -100.0% |
Q4 2021 | $223,000 | -12.9% | 16,488 | +17.5% | 0.00% | -50.0% |
Q3 2019 | $256,000 | -48.8% | 14,032 | -0.2% | 0.00% | -33.3% |
Q2 2019 | $500,000 | +8.9% | 14,059 | +3.0% | 0.00% | 0.0% |
Q1 2019 | $459,000 | +0.9% | 13,656 | -1.4% | 0.00% | 0.0% |
Q4 2018 | $455,000 | -46.0% | 13,850 | +0.3% | 0.00% | -40.0% |
Q3 2018 | $842,000 | +24.0% | 13,812 | -0.7% | 0.01% | +25.0% |
Q2 2018 | $679,000 | -52.1% | 13,915 | +4.4% | 0.00% | -55.6% |
Q1 2018 | $1,417,000 | +338.7% | 13,334 | +146.2% | 0.01% | +350.0% |
Q4 2017 | $323,000 | +19.6% | 5,415 | -51.8% | 0.00% | 0.0% |
Q3 2017 | $270,000 | +33.0% | 11,240 | +8.4% | 0.00% | +100.0% |
Q2 2017 | $203,000 | -16.5% | 10,366 | 0.0% | 0.00% | -50.0% |
Q1 2017 | $243,000 | +91.3% | 10,366 | 0.0% | 0.00% | +100.0% |
Q4 2016 | $127,000 | – | 10,366 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Camber Capital Management LP | 2,000,000 | $67,200,000 | 3.35% |
First Light Asset Management, LLC | 763,403 | $25,650,000 | 3.33% |
BRIDGER MANAGEMENT, LLC | 1,238,489 | $41,613,000 | 3.29% |
Rhenman & Partners Asset Management AB | 734,445 | $24,677,000 | 2.89% |
BB BIOTECH AG | 2,020,676 | $67,895,000 | 1.71% |
Gs Investments, Inc. | 54,200 | $1,821,120,000 | 1.43% |
Artal Group S.A. | 900,000 | $30,240,000 | 1.24% |
Cormorant Asset Management, LP | 500,000 | $16,800,000 | 1.14% |
TOBAM | 640,547 | $21,522,000 | 1.09% |
Bellevue Group AG | 430,026 | $14,449,000 | 0.80% |